Skip to content

Red flags and safety concerns

Research knowledge, not medical advice. This page records where things go wrong in the evidence, not what any individual should do.

TL;DR — Five things go wrong repeatedly. (1) Advanced fibrosis gets missed: FIB-4's rule-out sensitivity in an unselected primary-care population was 53.8%, not the high figure its reputation implies (Lindvig 2025, PMID 39674225), and its discrimination collapses at age extremes — AUC 0.51 in young people (van Kleef 2024, PMID 38513745). (2) HCC arises before cirrhosis: 38.5% of MASLD-related HCC occurs in non-cirrhotic livers, and only 32.8% of these patients had been under surveillance (Tan 2022, PMID 35255263). (3) Alcohol is misattributed in both directions: heavy alcohol use itself raises blood pressure, triglycerides and glucose, so diagnosing MASLD on a single cardiometabolic criterion above the weekly alcohol thresholds can attribute to metabolism a disease driven by alcohol (Arab 2025, PMID 39608457) — while mild-to-moderate alcohol use in metabolic syndrome is associated with worse liver outcomes, not better (Åberg 2023, PMID 36063967). (4) The steatotic liver is a different drug-safety environment, and statins are systematically underused because of a hepatotoxicity fear the data do not support: meta-analysis of 22 studies and 2,345 patients found ALT fell 35.4%, AST 31.8% and GGT 25.6% after statin treatment (Pastori 2022, PMID 34133035). (5) The alarm sounds late: once decompensation starts, median survival to death or transplant is 2.0 years (Noureddin 2024, PMID 38571305), and the disease is silent until then (Duell 2022, PMID 35418240).

1. Missing advanced fibrosis

Failure mode Evidence
FIB-4 rule-out sensitivity is low in unselected populations 53.8% (95% CI 48.5–58.9) at cut-off <1.3 in the DECIDE cohort (n=6,468), with NPV 95.8% — high NPV in low prevalence is not evidence of a good rule-out test (Lindvig 2025, PMID 39674225)
FIB-4 fails at age extremes AUC 0.51 in young people and 0.55 in older adults for liver stiffness ≥8 kPa, versus 0.86 and 0.75 for MAF-5 (van Kleef 2024, PMID 38513745)
Age-adapted FIB-4 thresholds do not fix it Lowered both NPV and PPV in every algorithm tested in a diabetology screening cohort (Caussy 2025, PMID 39887699)
Accuracy varies by region FIB-4 AUC 0.75 in Latin America vs 0.84 in MENA; Agile 4 0.85 in North America vs 0.96 in MENA, in one harmonised 41-country cohort (Younossi 2026, PMID 41100867)
A large indeterminate zone remains The explicit motivation for developing Agile 3+ and Agile 4 (Sanyal 2023, PMID 36375686)
High-risk disease is common in diabetes and often unlooked-for 14% advanced fibrosis and 6% cirrhosis in prospectively assessed adults aged ≥50 with T2D (Ajmera 2023, PMID 36410554)

The single most consequential structural failure is that most people with MASLD never enter a pathway at all — the disease is "typically silent until advanced and potentially irreversible liver impairment occurs", so "the majority of patients with NAFLD are unaware of having this serious condition" (Duell 2022, PMID 35418240). See noninvasive assessment.

2. Hepatocellular carcinoma outside the surveillance net

Finding Value
MASLD-related HCC arising in non-cirrhotic liver 38.5% (95% CI 27.9–50.2) vs 14.6% (8.7–23.4) for other aetiologies, p<0.0001
Patients with MASLD-related HCC who had undergone surveillance 32.8% (12.0–63.7) vs 55.7% (24.0–83.3), p<0.0001
Tumour diameter at diagnosis larger, p=0.0087

Source: Tan 2022, PMID 35255263. Because surveillance eligibility is anchored on cirrhosis, a large minority of these tumours cannot be caught by the current rule. HCC incidence in non-cirrhotic MASLD is 0.1–1.3 per 1,000 patient-years — too low to justify universal surveillance and too high to ignore across a third of the adult population (Huang 2021, PMID 33349658). Guidance extends surveillance consideration only to advanced fibrosis based on individual risk (Diaz 2025, PMID 40089151; Wattacheril 2023, PMID 37542503). See MASLD-related hepatocellular carcinoma.

3. Alcohol, in both directions

Under-attribution to alcohol. The MetALD expert position statement warns explicitly that heavy alcohol use contributes to hypertension, hypertriglyceridaemia and hyperglycaemia, so "caution should be exercised in the application of only one metabolic dysfunction criterion to diagnose MASLD… particularly in individuals exceeding weekly alcohol use thresholds of 140 g for women and 210 g for men". It recommends assessing recent and lifetime intake, quantified in grams per week, using validated questionnaires (AUDIT-C), objective biomarkers (phosphatidylethanol) and collateral history, and re-assessing over time (Arab 2025, PMID 39608457).

Over-tolerance of "moderate" drinking. Prospective evidence indicates mild-to-moderate alcohol use is associated with an increase in liver-related outcomes in this population; alcohol and metabolic factors act independently, jointly and synergistically, and central obesity measures such as waist-to-hip ratio predict liver-related outcomes better than BMI even among people drinking harmful quantities (Åberg 2023, PMID 36063967). The safety of moderate consumption in overweight and obese individuals has been questioned directly in the field (Sookoian 2016, PMID 26775630). Latin American guidance advises complete alcohol abstinence for patients with significant fibrosis (Diaz 2025, PMID 40089151).

Outcome consequence. Compared with MASLD, MetALD carries adverse liver outcomes at HR 1.56 (95% CI 1.50–1.62) and ALD at HR 2.33 (2.20–2.47) (Ochoa-Allemant 2025, PMID 40522656); liver-cancer risk rises stepwise to HR 3.16 for ALD and 22.0 for MASLD with viral hepatitis (Zeng 2025, PMID 39949980). See nomenclature and definitions.

Post-surgical alcohol. Bariatric surgery has been linked to increased risk of alcohol use disorder in human and rodent studies — a specific hazard in a population already at metabolic liver risk (Lefere 2021, PMID 34002452). See bariatric and metabolic surgery.

4. Drug safety in the steatotic liver

Concern Status of the evidence
Statin hepatotoxicity Not supported. In 22 studies and 2,345 NAFLD patients, statin treatment reduced ALT by 27.2 U/L (95% CI −35.25 to −19.15; −35.41%), AST by 18.82 U/L (−25.63 to −12.02; −31.78%) and GGT by 19.93 U/L (−27.10 to −12.77; −25.57%); cross-sectional studies showed no difference (Pastori 2022, PMID 34133035). The question was raised and largely settled two decades ago (Chalasani 2005, PMID 15789367)
Statin underuse Now quantified in a prospective population study of 6,055 people: 33% of statin-indicated participants with MASLD were untreated versus 19% without MASLD (p<0.001). Statin use was associated with lower odds of MASLD (aOR 0.76) and liver stiffness (aOR 0.65), but the observational associations do not establish benefit (Pustjens 2026, PMID 41861677)
Drug-induced liver injury in obesity Obesity alters susceptibility to DILI (Fromenty 2013, PMID 23298629); the steatotic liver is not a neutral substrate for hepatotoxic drugs
Medication-induced steatosis Methotrexate, amiodarone, tamoxifen and steroids should be excluded as causes of steatosis, particularly in lean patients (Long 2022, PMID 35842345); corticosteroids, tamoxifen and methotrexate are named among non-metabolic causes in the diagnostic definition (Tilg 2026, PMID 41212550)
Incretin-class risks AASLD flags acute kidney injury from dehydration, symptomatic gallbladder disease, pancreatitis, thyroid C-cell tumours, retinopathy progression and lean-mass loss (Bansal 2026, PMID 41201884). An unexplained neoplasm imbalance appeared in the semaglutide phase 2 (15% vs 8% any neoplasm; 3 malignancies vs 0) (Newsome 2021, PMID 33185364)
Resmetirom Diarrhoea and nausea more frequent than placebo; serious adverse events similar across arms (10.9%, 12.7%, 11.5%) (Harrison 2024, PMID 38324483). Expert guidance emphasises excluding cirrhosis before treating, since the drug is untested there (Noureddin 2024, PMID 39038768)
Obeticholic acid Pruritus in 51% at 25 mg vs 19% placebo — the tolerability signal that helped end the programme (Younossi 2019, PMID 31813633)
Pioglitazone Weight gain 2.5 kg versus placebo (Cusi 2016, PMID 27322798); discontinuation associated with disease recurrence (Bril 2023, PMID 36495442)
Perioperative mortality after bariatric surgery 0.6% within one year in a MASH cohort (gastrointestinal leak, respiratory failure) (Aminian 2021, PMID 34762106)

Herbal and dietary supplements — the exposure this population is most likely to have

Herbal and dietary supplements are a relevant competing cause of liver injury. They account for 20% of hepatotoxicity cases in the cited US research data, with anabolic steroids, green tea extract and multi-ingredient nutritional supplements the major implicated agents; anabolic steroids marketed for bodybuilding cause a prolonged cholestatic injury, while green tea extract and most others cause an acute hepatitis-like injury, and for multi-ingredient products the responsible constituent is usually unknown (Navarro 2017, PMID 27677775).

Turmeric is the clearest recent example and is directly relevant, since it is widely marketed for liver and metabolic health. Ten adjudicated cases in the US Drug-Induced Liver Injury Network, all since 2011 and six since 2017 (Halegoua-DeMarzio 2023, PMID 36252717):

Feature Finding
Demographics 8 of 10 women; 9 of 10 White; median age 56 (range 35–71)
Injury pattern hepatocellular in 9, mixed in 1; latency 1–4 months
Severity 5 hospitalised; 1 death from acute liver failure
Product analysis turmeric confirmed in all 7 products tested; 3 also contained piperine (black pepper), which increases curcumin bioavailability
Genetics HLA-B*35:01 in 7 of 10, 2 homozygous — allele frequency 0.450 against population controls of 0.056–0.069

The HLA-B*35:01 association gives the case series an immunological signal, although it does not by itself establish mechanism. Unexplained hepatocellular injury in someone with MASLD warrants a specific supplement history before rising transaminases are attributed to progression of the steatotic disease.

5. Alternative and coexisting diagnoses

The MASLD label is a positive diagnosis but not an exclusive one. Specific alternatives that must be excluded, particularly when the phenotype does not fit:

Setting What to exclude
Lean patient with steatosis HIV, lipodystrophy, lysosomal acid lipase deficiency, familial hypobetalipoproteinaemia, medication-induced steatosis (methotrexate, amiodarone, tamoxifen, steroids), inherited and genetic disorders, inflammatory disorders (Long 2022, PMID 35842345)
Any patient hepatitis C, iron overload, and specific medications as named causes of steatosis (Tilg 2026, PMID 41212550)
Steatosis with no metabolic criterion at all cryptogenic SLD, a distinct category — not MASLD (Rinella 2023, PMID 37363821)
Cirrhosis with no visible steatosis burnt-out MASLD; aetiology becomes unassignable on morphology (Brunt 2021, PMID 33111374; Liu 2025, PMID 40113099)
Discordant or indeterminate non-invasive tests AGA advises considering biopsy, and considering competing aetiologies (Wattacheril 2023, PMID 37542503)
Concurrent viral hepatitis MASLD with viral hepatitis carried liver-cancer HR 22.0 (95% CI 10.8–44.4) — the highest-risk combination in a 464,556-person cohort (Zeng 2025, PMID 39949980)

5b. Pregnancy

MASLD has been associated with adverse pregnancy outcomes in two nationwide cohorts using different designs.

Study Design Findings
Marxer 2025, PMID 40630617 Sweden 1992–2017; 240 births to 162 women with biopsy-proven disease retrospectively classified as MASLD vs 1,140 matched reference births; sibling analyses Preterm birth 16.7% vs 4.7%, aOR 3.41 (1.98–5.88) — and aOR 4.60 (2.00–10.60) against overweight/obese women without known MASLD, so measured obesity did not explain the association. Both medically indicated (aOR 11.90, 2.46–57.59) and spontaneous (aOR 2.42, 1.16–5.04) preterm birth. Caesarean section aOR 1.63 (1.17–2.27) overall but 1.20 (0.77–1.86) versus overweight/obese comparators. Apgar scores, congenital malformation, stillbirth and neonatal death did not differ. No gradient with MASLD severity (MASH/fibrosis/cirrhosis aOR 1.53, 0.23–10.02, wide intervals). Confirmed in sibling analyses
Jung 2026, PMID 41307877 Korea, 290,527 women with pre-pregnancy health checks and singleton deliveries, classified by SLD subtype Composite adverse pregnancy outcomes vs no SLD: MASLD aOR 2.44 (2.33–2.55), MetALD 2.45 (2.26–2.66), ALD 2.28 (2.11–2.47). Present for gestational diabetes, hypertensive disorders of pregnancy and preterm birth. Low birthweight: MASLD aOR 1.15 (1.05–1.27) and ALD 1.21 (1.02–1.43), but not MetALD (0.96, 0.79–1.18). Risk rose with the number of cardiometabolic risk factors (p for trend <0.0001)

The association persisted against BMI-matched comparators and in sibling analyses, reducing but not eliminating the possibility of residual confounding. The Swedish severity analysis was imprecise, so its null gradient should not be used to infer that the hepatic lesion is irrelevant. The Korean cohort found risk increasing with the number of cardiometabolic criteria. In the Swedish cohort, preterm birth increased while stillbirth, malformation and neonatal death did not.

6. Signals that risk is rising

Signal Meaning
LSM progression to ≥10 kPa Cumulative liver-related events 16% vs 4% in non-progressors; adjusted HR 4.0 (95% CI 1.8–8.9), p<0.01 (Gawrieh 2024, PMID 38762169)
LSM regression from ≥10 to <10 kPa Events 7% vs 32% in non-regressors; adjusted HR 0.25 (0.10–0.61), p<0.01 (PMID 38762169)
Persistently high Agile 3+ 30.1 liver-related events per 1,000 person-years vs 0.6 with persistently low scores (Lin 2024, PMID 38512249)
Clinically significant portal hypertension (HVPG ≥10 mmHg) 5-year decompensation 30.7% vs 9.4%; liver-related mortality 21.4% vs 0.8%; variceal bleeding did not occur without CSPH (Paternostro 2024, PMID 38823501)
First decompensation Cause-specific hazard of liver-related death rises 18.9-fold (95% CI 10.8–32.9) (Pennisi 2025, PMID 40550340)
Ascites as first event The most common first decompensation, in 69.5% of cases; median survival to death or transplant 2.0 years (Noureddin 2024, PMID 38571305)
Failure to respond at one year Consensus response definition is ≥30% LSM reduction or ≥0.5-point ELF reduction; non-response may be suspected if ALT or non-invasive tests worsen (Younossi 2026, PMID 41950980; Bansal 2026, PMID 41201884)

The bidirectionality in the Gawrieh data is important: in 1,403 participants over a mean 4.4 years with 89 liver-related events (annual incidence 1.5 per 100, 95% CI 1.2–1.8), 29% progressed to LSM ≥10 kPa while 44% regressed to <10 kPa. Change in stiffness carries prognostic information in both directions, which means a single measurement understates what serial measurement can detect.

7. Where the specialty boundary itself is a hazard

Cardiovascular disease is the leading cause of death in the general MASLD population and extrahepatic cancer the largest contributor to excess mortality in biopsy cohorts (cardiovascular and extrahepatic outcomes), while diagnosis and follow-up run through hepatology. The ADA's framing is that liver health "has not been at the forefront of complications tracked for disease prevention, as traditionally done for diabetic retinopathy, nephropathy, or neuropathy" (Cusi 2025, PMID 40434108); the public-health consensus records that responses are "weak and fragmented" and the disease "absent from nearly all national and international strategies and policies for non-communicable diseases" (Lazarus 2022, PMID 34707258). Neither observation has been converted into a tested care model.

Open questions

  • How often is a rising transaminase in MASLD actually supplement-induced liver injury? Herbal and dietary supplements cause 20% of US hepatotoxicity (PMID 27677775) and this population is heavily exposed, yet no MASLD cohort has reported adjudicated DILI incidence or systematically collected supplement histories. HLA-B*35:01 typing distinguishes turmeric injury (PMID 36252717) and is not used clinically.
  • Should MASLD change antenatal management? Preterm birth was roughly three- to four-fold more common in the biopsy-based MASLD cohort after adjustment and remained elevated in sibling analyses; adverse pregnancy outcomes were ~2.4-fold more common across SLD subtypes in a separate study (PMIDs: 40630617, 41307877). Residual confounding remains possible. No obstetric guideline retrieved on 2026-09-02 identified MASLD as a risk factor, and the imprecise severity analysis does not establish whether liver stage should affect triage.
  • What is the false-negative rate of guideline-recommended pathways in practice? Sequential FIB-4→VCTE achieved 66% sensitivity at standard cut-offs in an IPD meta-analysis (PMID 34001645). A prospective 186-person diagnostic study with same-month FIB-4, ELF, MRE and biopsy found FIB-4 sensitivity 57% and showed that a sequential FIB-4-first pathway excluded 43% of fibrotic MASLD from second-line testing; concurrent FIB-4-or-ELF improved sensitivity to 87% at 64% specificity (Allen 2026, PMID 42566274). The remaining dated gap is outcomes from a deployed health-system pathway, not absence of prospective false-negative measurement.
  • How much alcohol is being under-reported? MetALD is defined by self-reported grams per week, and the position statement's recommendation to use phosphatidylethanol implies current classification is misclassified by an unmeasured amount (PMID 39608457).
  • Is statin underuse consequential? Underuse is measurable: 33% of statin-indicated people with MASLD versus 19% without MASLD were untreated (PMID 41861677). Excess cardiovascular events attributable to that gap have not been estimated, and the lower-stiffness association with statin use remains observational.
  • Does the neoplasm imbalance in the semaglutide phase 2 replicate? 15% versus 8% any neoplasm and 3 versus 0 malignancies (PMID 33185364), reported without interpretation and, in retrieved searches, not addressed by a pooled MASH-population safety analysis.
  • What proportion of "cryptogenic" cirrhosis is burnt-out MASLD? Steatosis disappears at the cirrhotic stage (PMIDs: 33111374, 40113099), and no study has quantified the resulting misattribution.

References

  1. Lindvig KP, Thorhauge KH, Hansen JK, et al. Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study. Lancet Gastroenterol Hepatol. 2025;10(1):55-67. PMID 39674225
  2. van Kleef LA, Francque SM, Prieto-Ortiz JE, et al. Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction. Gastroenterology. 2024;167(2):357-367.e9. PMID 38513745
  3. Caussy C, Vergès B, Leleu D, et al. Screening for MASLD-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study. Diabetes Care. 2025;48(6):877-886. PMID 39887699
  4. Younossi ZM, de Avila L, Petta S, et al. Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study. Hepatology. 2026;84(1):161-174. PMID 41100867
  5. Sanyal AJ, Foucquier J, Younossi ZM, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol. 2023;78(2):247-259. PMID 36375686
  6. Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471-478. PMID 36410554
  7. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of NAFLD-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521-530. PMID 35255263
  8. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-238. PMID 33349658
  9. Arab JP, Díaz LA, Rehm J, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82(4):744-756. PMID 39608457
  10. Åberg F, Byrne CD, Pirola CJ, et al. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. J Hepatol. 2023;78(1):191-206. PMID 36063967
  11. Sookoian S, Pirola CJ. How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals? Gastroenterology. 2016;150(8):1698-1703.e2. PMID 26775630
  12. Ochoa-Allemant P, Hubbard RA, Kaplan DE, et al. Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease. JAMA Intern Med. 2025;185(8):986-995. PMID 40522656
  13. Zeng H, Fang L, Yang Z, et al. Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population-based study. MedComm (2020). 2025;6(2):e70087. PMID 39949980
  14. Pastori D, Pani A, Di Rocco A, et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441-451. PMID 34133035
  15. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41(4):690-5. PMID 15789367
  16. Mallet M, Bouam S, Nahon P. Editorial: statin use in patients with NAFLD-safety concerns, decreased awareness or both? Aliment Pharmacol Ther. 2021;54(11-12):1499-1500. PMID 34741325
  17. Zhou XD, Kim SU, Yip TC, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73(11):1883-1892. PMID 39089860
  18. Fromenty B. Drug-induced liver injury in obesity. J Hepatol. 2013;58(4):824-6. PMID 23298629
  19. Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022;163(3):764-774.e1. PMID 35842345
  20. Tilg H, Petta S, Stefan N, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review. JAMA. 2026;335(2):163-174. PMID 41212550
  21. Bansal MB, Patton H, Morgan TR, et al. Semaglutide therapy for MASH: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83(5):1326-1340. PMID 41201884
  22. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID 33185364
  23. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PMID 38324483
  24. Noureddin M, Charlton MR, Harrison SA, et al. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom. Clin Gastroenterol Hepatol. 2024;22(12):2367-2377. PMID 39038768
  25. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a phase 3 trial. Lancet. 2019;394(10215):2184-2196. PMID 31813633
  26. Cusi K, Orsak B, Bril F, et al. Long-Term Pioglitazone Treatment for Patients With NASH and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305-15. PMID 27322798
  27. Bril F, Kalavalapalli S, Lomonaco R, et al. Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence. Diabetes Obes Metab. 2023;25(4):1112-1116. PMID 36495442
  28. Aminian A, Al-Kurd A, Wilson R, et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven NASH. JAMA. 2021;326(20):2031-2042. PMID 34762106
  29. Lefere S, Onghena L, Vanlander A, et al. Bariatric surgery and the liver-Mechanisms, benefits, and risks. Obes Rev. 2021;22(9):e13294. PMID 34002452
  30. Gawrieh S, Vilar-Gomez E, Wilson LA, et al. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD. J Hepatol. 2024;81(4):600-608. PMID 38762169
  31. Lin H, Lee HW, Yip TC, et al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease. JAMA. 2024;331(15):1287-1297. PMID 38512249
  32. Paternostro R, Kwanten WJ, Hofer BS, et al. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD. J Hepatol. 2024;81(5):827-836. PMID 38823501
  33. Pennisi G, Di Maria G, Wong VW, et al. Impact of first and further decompensation in patients with compensated ACLD due to MASLD. J Hepatol. 2025;83(6):1266-1277. PMID 40550340
  34. Noureddin N, Huang DQ, Bettencourt R, et al. Natural history of clinical outcomes and hepatic decompensation in MASLD. Aliment Pharmacol Ther. 2024;59(12):1521-1526. PMID 38571305
  35. Younossi ZM, Kalligeros M, Wong VW, et al. Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in MASLD. Clin Gastroenterol Hepatol. 2026;24(9):2333-2347. PMID 41950980
  36. Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e185. PMID 35418240
  37. Cusi K, Abdelmalek MF, Apovian CM, et al. MASLD in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-1082. PMID 40434108
  38. Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60-78. PMID 34707258
  39. Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006-1019. PMID 34001645
  40. Brunt EM, Kleiner DE, Carpenter DH, et al. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 2021;73(5):2028-2038. PMID 33111374
  41. Liu WY, Zheng KI, Byrne CD, et al. From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced MASLD. Gastroenterology. 2025;169(2):326-336.e4. PMID 40113099
  42. Wattacheril JJ, Abdelmalek MF, Lim JK, et al. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of NAFLD: Expert Review. Gastroenterology. 2023;165(4):1080-1088. PMID 37542503
  43. Diaz LA, Arab JP, Idalsoaga F, et al. Updated recommendations for the management of MASLD by the Latin American working group. Ann Hepatol. 2025;30(2):101903. PMID 40089151
  44. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. PMID 37363821
  45. Pustjens J, et al. Underuse of statins in MASLD despite population-based associations with lower liver stiffness. JHEP Rep. 2026;8(4):101764. PMID 41861677
  46. Allen AM, et al. Sequential FIB-4-based testing limits detection of fibrotic MASLD despite optimized ELF thresholds. Hepatol Commun. 2026;10(9):e1012. PMID 42566274
  47. Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363-373. PMID 27677775
  48. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver Injury Associated with Turmeric-A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. 2023;136(2):200-206. PMID 36252717
  49. Marxer CA, Ebrahimi F, Bergman D, et al. Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study. EClinicalMedicine. 2025;83:103238. PMID 40630617
  50. Jung YM, Kim T, Oh MJ, et al. Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study. Hepatol Int. 2026;20(1):69-80. PMID 41307877